PM359: Clinical Trials

1 trial of PM359, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 enrolling by invitation. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Enrolling by invitation 1
Phase 21Enrolling by invitation 1

Follow PM359: new trials by email Literature Review of PM359 trials Research Report on PM359

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
PM359 - Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Phase 1 / Phase 2Enrolling by invitationPrime Medicine, Inc.122024-10-172026-04-06

Conditions studied

Granulomatous Disease, Chronic (1)

Sponsors

Prime Medicine, Inc. (1)

Countries

Canada (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 41358590